AR076551A1 - Compuestos de 1-cianoetilheterociclilcarboxamida sustituida, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por dppi - Google Patents
Compuestos de 1-cianoetilheterociclilcarboxamida sustituida, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por dppiInfo
- Publication number
- AR076551A1 AR076551A1 ARP100101567A ARP100101567A AR076551A1 AR 076551 A1 AR076551 A1 AR 076551A1 AR P100101567 A ARP100101567 A AR P100101567A AR P100101567 A ARP100101567 A AR P100101567A AR 076551 A1 AR076551 A1 AR 076551A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- independently
- cycloalkyl
- hydrogen
- heterocyclic ring
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102100029921 Dipeptidyl peptidase 1 Human genes 0.000 title 1
- 101710087078 Dipeptidyl peptidase 1 Proteins 0.000 title 1
- 150000003857 carboxamides Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 4
- 125000003341 7 membered heterocyclic group Chemical group 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 229920006395 saturated elastomer Polymers 0.000 abstract 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- -1 nitro, cyano, mercapto Chemical class 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 239000011593 sulfur Substances 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- SOIIHESTBYNJRH-PMPSAXMXSA-N (3r,6r,8as)-6-(benzylsulfonylamino)-n-[3-(diaminomethylideneamino)propyl]-5-oxo-2,3,6,7,8,8a-hexahydro-[1,3]thiazolo[3,2-a]pyridine-3-carboxamide Chemical group N([C@@H]1CC[C@@H]2SC[C@H](N2C1=O)C(=O)NCCCN=C(N)N)S(=O)(=O)CC1=CC=CC=C1 SOIIHESTBYNJRH-PMPSAXMXSA-N 0.000 abstract 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- ZOUTYVWHWSUKPL-RNCFNFMXSA-N C[C@H](CS)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O Chemical compound C[C@H](CS)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O ZOUTYVWHWSUKPL-RNCFNFMXSA-N 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- DSODRWWHAUGSGD-UHFFFAOYSA-N [5-(carbamimidoylsulfanylmethyl)thiophen-2-yl]methyl carbamimidothioate;dihydrochloride Chemical compound Cl.Cl.NC(=N)SCC1=CC=C(CSC(N)=N)S1 DSODRWWHAUGSGD-UHFFFAOYSA-N 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrane Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Composiciones farmacéuticas de los mismos y su uso en el tratamiento del asma, EPOC y rinitis alérgica. Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1) donde y representa 0, 1 o 2; m y n son de manera independiente 0, 1, 2 o 3 (con lo cual la suma de m y n es igual a 1, 2 o 3); R1 es alquilo C1-3 sustituido opcionalmente con uno o más sustituyentes seleccionados entre halogeno, hidroxi o alcoxi C1-3; R2 se selecciona entre hidrogeno, halogeno, CN, CF3, alquilo C1-3 o alcoxi C1-3; Q representa fenilo, un sistema de anillos heteroarilo de entre 5 y 10 miembros que contiene por lo menos un heteroátomo en el anillo seleccionado entre nitrogeno, oxígeno y azufre, o Q es de la formula A donde X es CH o N y B es un anillo heterocíclico de 5 o 6 miembros que contiene entre 1 y 3 heteroátomos en el anillo seleccionados de manera independiente entre nitrogeno, oxígeno y azufre; donde el fenilo, el sistema de anillos heteroarilo y el sistema de anillos de la formula A está sustituido opcionalmente con entre 1 y 3 sustituyentes seleccionados de manera independiente entre halogeno, carboxilo, hidroxilo, oxo, nitro, ciano, mercapto, alquilo C1-6 (a su vez sustituido opcionalmente con hidroxilo, alcoxi C1-6, NR65R66, fenilo o morfolinilo), cicloalquilo C3-6, alquenilo C2-6, trifluorometilo, alcoxi C1-6, alquilcarbonilo C1-6, alquilcarboniloxi C1-6, alcoxicarbonilo C1-6, -NR53R54, -C(O)NR55R56, NR57C(O)R58, SO2NR59R60, NR61SO2R62, S(O)vR63, OS(O2)R64, benciloxi y alquilpiperazinilo C1-6; R53 y R54 representan de manera independiente entre sí hidrogeno, alquilo C1-6 o cicloalquilo C3-6, o R53 y R forman, junto con el átomo de nitrogeno al cual están unidos, un anillo heterocíclico saturado de entre 4 y 7 miembros, v es 0,1 o 2; R55 y R56 representan de manera independiente entre sí hidrogeno, alquilo C1-6 o cicloalquilo C3-6, o R55 y R56 forman, junto con el átomo de nitrogeno al cual están unidos, un anillo heterocíclico saturado de entre 4 y 7 miembros, R59 y R60 representan de manera independiente entre sí hidrogeno, alquilo C1-6 o cicloalquilo C3-6, o R59 y R60 forman, junto con el átomo de nitrogeno al cual están unidos, un anillo heterocíclico saturado de entre 4 y 7 miembros; cada R57, R58, R61, R62 R63 y R64 representa de manera independiente un átomo de hidrogeno o un grupo alquilo C1-6 o cicloalquilo C3-6; R65 y R66 representan de manera independiente entre si hidrogeno, alquilo C1-6 o cicloalquilo C3-6, o R65 y R66 forman, junto con el átomo de nitrogeno al cual están unidos, un anillo heterocíclico saturado de entre 4 y 7 miembros; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17627909P | 2009-05-07 | 2009-05-07 | |
| US18562909P | 2009-06-10 | 2009-06-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR076551A1 true AR076551A1 (es) | 2011-06-22 |
Family
ID=42271991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101567A AR076551A1 (es) | 2009-05-07 | 2010-05-07 | Compuestos de 1-cianoetilheterociclilcarboxamida sustituida, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por dppi |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8193239B2 (es) |
| EP (1) | EP2427445A1 (es) |
| JP (1) | JP2012526093A (es) |
| KR (1) | KR20120034639A (es) |
| CN (1) | CN102574830A (es) |
| AR (1) | AR076551A1 (es) |
| AU (1) | AU2010244218B2 (es) |
| BR (1) | BRPI1015540A2 (es) |
| CA (1) | CA2759581A1 (es) |
| CL (1) | CL2011002787A1 (es) |
| CO (1) | CO6450612A2 (es) |
| CR (1) | CR20110579A (es) |
| CU (1) | CU20110204A7 (es) |
| EA (1) | EA201190235A1 (es) |
| EC (1) | ECSP11011439A (es) |
| IL (1) | IL215615A0 (es) |
| MX (1) | MX2011011661A (es) |
| SG (1) | SG175090A1 (es) |
| TW (1) | TW201041889A (es) |
| UY (1) | UY32611A (es) |
| WO (1) | WO2010128324A1 (es) |
| ZA (1) | ZA201108962B (es) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS58855B1 (sr) | 2009-06-10 | 2019-07-31 | Chugai Pharmaceutical Co Ltd | Tetraciklična jedinjenja |
| JP4918630B1 (ja) | 2010-08-20 | 2012-04-18 | 中外製薬株式会社 | ４環性化合物を含む組成物 |
| AU2012214405B2 (en) * | 2011-02-11 | 2015-07-23 | Glaxosmithkline Intellectual Property Development Limited | Cathepsin C inhibitors |
| WO2012119941A1 (en) | 2011-03-04 | 2012-09-13 | Prozymex A/S | Peptidyl nitrilcompounds as peptidase inhibitors |
| MX389105B (es) | 2012-09-25 | 2025-03-20 | Chugai Pharmaceutical Co Ltd | Inhibidor de quinasas reordenadas durante la transfeccion (ret). |
| EP2970228B1 (en) | 2013-03-14 | 2017-05-10 | Boehringer Ingelheim International GmbH | Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano-methyl)-amides inhibitors of cathepsin c |
| US8877775B2 (en) | 2013-03-14 | 2014-11-04 | Boehringer Ingelheim International Gmbh | Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C |
| WO2014140081A1 (en) * | 2013-03-14 | 2014-09-18 | Boehringer Ingelheim International Gmbh | Substituted bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c |
| CN105026395B (zh) | 2013-03-14 | 2018-07-20 | 勃林格殷格翰国际有限公司 | 取代的氮杂双环酰胺类组织蛋白酶c抑制剂及其药物组合物和制药用途 |
| AU2014282769A1 (en) | 2013-06-21 | 2015-12-17 | Lupin Limited | Substituted heterocyclic compounds as CRAC modulators |
| EP3013810A1 (en) | 2013-06-24 | 2016-05-04 | Lupin Limited | Chromane and chromene derivatives and their use as crac modulators |
| WO2015032945A1 (en) * | 2013-09-09 | 2015-03-12 | Prozymex A/S | Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors |
| NO2699580T3 (es) * | 2014-01-24 | 2018-02-24 | ||
| KR20220042486A (ko) | 2014-04-25 | 2022-04-05 | 추가이 세이야쿠 가부시키가이샤 | 4환성 화합물의 신규 결정 |
| CN106456651A (zh) | 2014-04-25 | 2017-02-22 | 中外制药株式会社 | 以高用量含有四环性化合物的制剂 |
| ES2664810T3 (es) | 2014-06-12 | 2018-04-23 | Pfizer Limited | Derivados de imidazopiridazina como moduladores de la actividad del receptor GABAA |
| WO2016016242A1 (en) | 2014-08-01 | 2016-02-04 | Boehringer Ingelheim International Gmbh | Substituted oxetanes and their use as inhibitors of cathepsin c |
| TWI718102B (zh) | 2014-08-08 | 2021-02-11 | 日商中外製藥股份有限公司 | ４環性化合物的非晶質體 |
| NZ728684A (en) | 2014-09-12 | 2022-09-30 | Boehringer Ingelheim Int | Spirocyclic inhibitors of cathepsin c |
| CA2973857C (en) | 2015-01-16 | 2023-11-07 | Chugai Seiyaku Kabushiki Kaisha | Combination drug |
| WO2016139355A1 (en) | 2015-03-05 | 2016-09-09 | Prozymex A/S | N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors |
| EP3265452B1 (en) * | 2015-03-05 | 2020-03-04 | Neuprozyme Therapeutics ApS | Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors |
| CN106478629A (zh) * | 2015-08-24 | 2017-03-08 | 上海医药工业研究院 | 一种利格列汀的制备工艺 |
| US11319299B2 (en) | 2016-03-01 | 2022-05-03 | Propellon Therapeutics Inc. | Substituted carboxamides as inhibitors of WDR5 protein-protein binding |
| AU2017226005A1 (en) | 2016-03-01 | 2018-09-06 | Propellon Therapeutics Inc. | Inhibitors of WDR5 protein-protein binding |
| JP2019522039A (ja) * | 2016-07-29 | 2019-08-08 | インスメッド インコーポレイテッド | 気管支拡張症の処置のための特定の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニルエチル］−１，４−オキサゼパン−２−カルボキサミド |
| MA52424B1 (fr) | 2018-03-01 | 2025-04-30 | Astrazeneca Ab | Compositions pharmaceutiques comprenant du (2s)--((1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl)-1,4-oxazepane-2-carboxamide |
| US20210252015A1 (en) * | 2018-07-17 | 2021-08-19 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating inflammatory bowel disease |
| CA3106269A1 (en) | 2018-07-17 | 2020-01-23 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis |
| IL281079B2 (en) | 2018-09-04 | 2024-12-01 | Chugai Pharmaceutical Co Ltd | Method of producing a tetracyclic compound |
| WO2022042591A1 (zh) | 2020-08-26 | 2022-03-03 | 四川海思科制药有限公司 | 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途 |
| WO2022117059A1 (zh) | 2020-12-04 | 2022-06-09 | 瑞石生物医药有限公司 | 组织蛋白酶c小分子抑制剂及其医药用途 |
| CN116783189B (zh) * | 2021-02-05 | 2026-01-30 | 上海复星医药产业发展有限公司 | 含1，4-氧杂氮杂环庚烷的并环类衍生物 |
| KR20240150486A (ko) * | 2022-02-22 | 2024-10-15 | 하이스코 파마수티컬즈 피티이. 엘티디. | 질소-함유 헤테로사이클릭 화합물의 제조 방법 |
| EP4538271A4 (en) | 2022-06-07 | 2025-10-08 | Reistone Biopharma Company Ltd | POLYMORPH OF BENZO[C]CHROMANE COMPOUND, ITS PREPARATION METHOD AND ITS USE |
| CA3255979A1 (en) | 2022-06-07 | 2025-03-18 | Reistone Biopharma Company Limited | PHARMACEUTICALLY ACCEPTABLE SALT OF A BENZO[C]CHROMANE COMPOUND, POLYMORPHIC FORM AND USE OF A PHARMACEUTICALLY ACCEPTABLE SALT |
| EP4551554A1 (en) | 2022-07-06 | 2025-05-14 | Chiesi Farmaceutici S.p.A. | Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors |
| AU2024206233A1 (en) | 2023-01-06 | 2025-08-21 | Insmed Incorporated | Novel, reversible dpp1 inhibitors and uses thereof |
| WO2025059526A1 (en) * | 2023-09-15 | 2025-03-20 | Insmed Incorporated | Dipeptidyl peptidase 1 inhibitors and uses thereof |
| WO2025165806A1 (en) * | 2024-01-29 | 2025-08-07 | Insmed Incorporated | Dipeptidyl peptidase 1 inhibitors and uses thereof |
| WO2025162472A1 (en) * | 2024-01-31 | 2025-08-07 | Insmed Incorporated | Linear dipeptidyl peptidase 1 inhibitors and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| ES2264937T3 (es) | 1999-07-30 | 2007-02-01 | Boehringer Ingelheim Pharmaceuticals Inc. | Nuevos compuestos derivados de succinato, utiles como inhibidores de cisteina-proteasa. |
| ES2270898T3 (es) | 1999-12-24 | 2007-04-16 | F. Hoffmann-La Roche Ag | Derivados de nitrilo como inhibidores de catepsina k. |
| ATE370943T1 (de) | 2001-06-27 | 2007-09-15 | Smithkline Beecham Corp | Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren |
| CN1990469A (zh) | 2001-06-27 | 2007-07-04 | 史密丝克莱恩比彻姆公司 | 作为二肽酶抑制剂的氟代吡咯烷 |
| US6995180B2 (en) * | 2002-10-23 | 2006-02-07 | Bristol Myers Squibb Company | Glycinenitrile-based inhibitors of dipeptidyl peptidase IV and methods |
| EP1638925A1 (en) * | 2003-06-18 | 2006-03-29 | Prozymex A/S | Protease inhibitors |
| US7504413B2 (en) | 2004-05-06 | 2009-03-17 | Cytokinetics, Inc. | N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases |
-
2010
- 2010-05-05 KR KR1020117029122A patent/KR20120034639A/ko not_active Withdrawn
- 2010-05-05 SG SG2011072774A patent/SG175090A1/en unknown
- 2010-05-05 EP EP10719056A patent/EP2427445A1/en not_active Withdrawn
- 2010-05-05 EA EA201190235A patent/EA201190235A1/ru unknown
- 2010-05-05 CA CA2759581A patent/CA2759581A1/en not_active Abandoned
- 2010-05-05 MX MX2011011661A patent/MX2011011661A/es not_active Application Discontinuation
- 2010-05-05 WO PCT/GB2010/050736 patent/WO2010128324A1/en not_active Ceased
- 2010-05-05 CN CN2010800307151A patent/CN102574830A/zh active Pending
- 2010-05-05 JP JP2012509091A patent/JP2012526093A/ja active Pending
- 2010-05-05 BR BRPI1015540A patent/BRPI1015540A2/pt not_active IP Right Cessation
- 2010-05-05 AU AU2010244218A patent/AU2010244218B2/en not_active Ceased
- 2010-05-06 TW TW099114513A patent/TW201041889A/zh unknown
- 2010-05-06 UY UY0001032611A patent/UY32611A/es not_active Application Discontinuation
- 2010-05-06 US US12/774,996 patent/US8193239B2/en not_active Expired - Fee Related
- 2010-05-07 AR ARP100101567A patent/AR076551A1/es unknown
-
2011
- 2011-10-06 IL IL215615A patent/IL215615A0/en unknown
- 2011-10-31 CO CO11147437A patent/CO6450612A2/es not_active Application Discontinuation
- 2011-11-07 CU CU20110204A patent/CU20110204A7/es unknown
- 2011-11-07 EC EC2011011439A patent/ECSP11011439A/es unknown
- 2011-11-07 CL CL2011002787A patent/CL2011002787A1/es unknown
- 2011-11-07 CR CR20110579A patent/CR20110579A/es unknown
- 2011-12-06 ZA ZA2011/08962A patent/ZA201108962B/en unknown
-
2012
- 2012-06-04 US US13/488,248 patent/US20120329775A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP11011439A (es) | 2011-12-30 |
| KR20120034639A (ko) | 2012-04-12 |
| CN102574830A (zh) | 2012-07-11 |
| SG175090A1 (en) | 2011-11-28 |
| JP2012526093A (ja) | 2012-10-25 |
| BRPI1015540A2 (pt) | 2019-09-24 |
| US20100286118A1 (en) | 2010-11-11 |
| AU2010244218A1 (en) | 2011-11-03 |
| CO6450612A2 (es) | 2012-05-31 |
| AU2010244218B2 (en) | 2012-07-19 |
| US8193239B2 (en) | 2012-06-05 |
| UY32611A (es) | 2010-12-31 |
| CL2011002787A1 (es) | 2012-06-22 |
| EP2427445A1 (en) | 2012-03-14 |
| CR20110579A (es) | 2012-01-09 |
| IL215615A0 (en) | 2011-12-29 |
| EA201190235A1 (ru) | 2012-05-30 |
| CU20110204A7 (es) | 2012-03-15 |
| CA2759581A1 (en) | 2010-11-11 |
| WO2010128324A1 (en) | 2010-11-11 |
| ZA201108962B (en) | 2012-08-29 |
| TW201041889A (en) | 2010-12-01 |
| MX2011011661A (es) | 2011-11-18 |
| US20120329775A1 (en) | 2012-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR076551A1 (es) | Compuestos de 1-cianoetilheterociclilcarboxamida sustituida, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por dppi | |
| PE20220143A1 (es) | Agonistas de glp-1r y usos de los mismos | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| ECSP099755A (es) | Derivados de pirrolopiridina y su uso como inhibidores de bace | |
| AR083872A1 (es) | Derivados de acido carbamoil-cicloalquil-acetico sustituidos como inhibidores de nep | |
| AR061564A1 (es) | Derivados de isoindoles, composiciones farmaceuticas y usos | |
| AR086100A1 (es) | Compuestos de cromenona y composiciones farmaceuticas que los contienen | |
| AR077417A1 (es) | Compuesto triazolopiridina y su accion como inhibidor de prolil hidroxilasa o agente inductor de la produccion de eritropoyetina | |
| AR075729A1 (es) | Derivados de benzofuranilo, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad y/o diabetes. | |
| AR067662A1 (es) | Derivados de benzo[d]isoxazol-3-il-piperidina, medicamentos que los contienen y usos terapeuticos para enfermedades asociadas al sistema nervioso. | |
| AR086198A1 (es) | Inhibidores sustituidos de acetil-coa carboxilasa y composiciones farmaceuticas que los contienen | |
| AR072791A1 (es) | DERIVADOS DE TIAZOLIDIN-2, 4-DIONA, MÉTODOS PARA SU PREPARACIoN, COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE Y SU USO EN LA ELABORACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DEL CÁNCER. | |
| EA201290260A1 (ru) | Бензимидазол-имидазольные производные | |
| CL2020001919A1 (es) | Inhibidores de endonucleasa cap-dependientes. | |
| AR067646A1 (es) | Ariloxazoles sustituidos y su uso | |
| AR078408A1 (es) | Derivados de indol como moduladores de los crac | |
| EA201791271A1 (ru) | ТИАЗОЛЫ, ЗАМЕЩЕННЫЕ КАРБОКСАМИДОМ ИЛИ СУЛЬФОНАМИДОМ, И РОДСТВЕННЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ДЛЯ ОРФАННОГО ЯДЕРНОГО РЕЦЕПТОРА RORγ | |
| UY29457A1 (es) | Compuestos novedosos de derivados de aminosulfonilo | |
| AR089550A1 (es) | Compuestos quimicos | |
| AR110282A1 (es) | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR101196A1 (es) | Compuestos de pirimidina sustituidos | |
| UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
| AR070485A1 (es) | Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica | |
| AR072809A1 (es) | Compuesto de (3- piridinilcarbonil)-4-(fenilsulfonilpiperazina ), su uso para la elaboracion de unmedicamento para el tratamiento del dolor y composicion farmaceutica que lo comprende |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |